JP7697974B2 - Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物 - Google Patents

Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物 Download PDF

Info

Publication number
JP7697974B2
JP7697974B2 JP2022567286A JP2022567286A JP7697974B2 JP 7697974 B2 JP7697974 B2 JP 7697974B2 JP 2022567286 A JP2022567286 A JP 2022567286A JP 2022567286 A JP2022567286 A JP 2022567286A JP 7697974 B2 JP7697974 B2 JP 7697974B2
Authority
JP
Japan
Prior art keywords
ethyl
oxo
trifluoromethoxy
phenyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022567286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524133A5 (https=
JP2023524133A (ja
Inventor
スティーブン ユーライア ボウリン，
アミン モハメド カメル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2023524133A publication Critical patent/JP2023524133A/ja
Publication of JP2023524133A5 publication Critical patent/JP2023524133A5/ja
Application granted granted Critical
Publication of JP7697974B2 publication Critical patent/JP7697974B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2022567286A 2020-05-08 2021-05-06 Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物 Active JP7697974B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063021895P 2020-05-08 2020-05-08
US63/021,895 2020-05-08
PCT/IB2021/000304 WO2021224680A1 (en) 2020-05-08 2021-05-06 Substituted benzotriazinone metabolites of a gpr139 agonist

Publications (3)

Publication Number Publication Date
JP2023524133A JP2023524133A (ja) 2023-06-08
JP2023524133A5 JP2023524133A5 (https=) 2024-04-30
JP7697974B2 true JP7697974B2 (ja) 2025-06-24

Family

ID=76624075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567286A Active JP7697974B2 (ja) 2020-05-08 2021-05-06 Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物

Country Status (5)

Country Link
US (1) US12559465B2 (https=)
EP (1) EP4146635A1 (https=)
JP (1) JP7697974B2 (https=)
CA (1) CA3177117A1 (https=)
WO (1) WO2021224680A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220160A (es) 2019-09-16 2022-06-16 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
WO2021224680A1 (en) 2020-05-08 2021-11-11 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
CN116693545A (zh) * 2022-03-01 2023-09-05 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN116693536A (zh) * 2022-03-01 2023-09-05 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
CN121159462A (zh) * 2025-11-19 2025-12-19 杭州市第七人民医院(杭州市心理危机研究与干预中心) 喹唑啉酮类化合物及其在制备神经系统疾病药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535559A (ja) 2014-11-20 2017-11-30 武田薬品工業株式会社 Ｇｐｒ１３９のモジュレーターとしての４−オキソ−３，４−ジヒドロ−１，２，３−ベンゾトリアジン

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
EP0315390B1 (en) 1987-11-04 1994-07-20 Beecham Group Plc Novel 4-oxobenzotriazines and 4-oxoquinazolines
JP4079727B2 (ja) * 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
AU2004261283B2 (en) 2003-07-31 2008-05-01 Irm, Llc Bicyclic compounds and compositions as PDF inhibitors
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
WO2014152917A2 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv Physiological ligands for gpr139
CR20220160A (es) 2019-09-16 2022-06-16 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
WO2021224680A1 (en) 2020-05-08 2021-11-11 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
US20230310441A1 (en) 2020-09-21 2023-10-05 Takeda Pharmaceutical Company Treatment for schizophrenia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535559A (ja) 2014-11-20 2017-11-30 武田薬品工業株式会社 Ｇｐｒ１３９のモジュレーターとしての４−オキソ−３，４−ジヒドロ−１，２，３−ベンゾトリアジン

Also Published As

Publication number Publication date
US12559465B2 (en) 2026-02-24
EP4146635A1 (en) 2023-03-15
US20230227416A1 (en) 2023-07-20
WO2021224680A8 (en) 2023-01-05
WO2021224680A1 (en) 2021-11-11
CA3177117A1 (en) 2021-11-11
JP2023524133A (ja) 2023-06-08

Similar Documents

Publication Publication Date Title
JP7697974B2 (ja) Ｇｐｒ１３９アゴニストの置換ベンゾトリアジノン代謝物
CA3119656A1 (en) Macrocyclic compounds and their use in the treatment of disease
CN103717593B (zh) 调节激酶的组合物和方法
JP2017502073A (ja) 置換ベンゾオキサジン及び関連化合物
JP2013523658A (ja) キナーゼ阻害剤としてのピラゾリル‐ピリミジン
CN102307868B (zh) 作为抗癌剂的吲哚衍生物
JP6076498B2 (ja) ナンセンス突然変異抑制剤としてのピリミド［４，５−ｂ］キノリン−４，５（３ｈ，１０ｈ）−ジオン
CN106518841A (zh) 环己烷衍生物或其立体异构体或盐及其制备与应用
CA2753135A1 (fr) Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique
CN101679272B (zh) 作为腺苷a3受体配体的三唑并[1,5-a]喹啉类
TW201625610A (zh) 萘啶二酮（ｎａｐｈｔｈｙｒｉｄｉｎｅｄｉｏｎｅ）衍生物
CN106414443B (zh) 吡啶并嘧啶二酮衍生物
CA3094481A1 (en) Phenothiazine derivatives and uses thereof
CN108929329B (zh) 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物
JP7763538B2 (ja) Ｐａｒｐ７阻害剤及びその使用
JP2002525373A (ja) ２−ピペラジノアルキルアミノベンゾアゾール誘導体：ドーパミン受容体サブタイプ特殊リガンド
JP2004512364A (ja) 中枢神経系疾患の治療のためのスルホンアミド
JP7782023B2 (ja) Ａｈｒアゴニスト
KR20240009422A (ko) Sting 시그널링의 소분자 억제제 조성물 및 사용 방법
RU2782469C2 (ru) Апоптоз-индуцирующие агенты
KR20260025059A (ko) 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물
HK40083035B (zh) Parp7抑制剂及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250612

R150 Certificate of patent or registration of utility model

Ref document number: 7697974

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150